Fananserin
CAS: 127625-29-0
Ref. 3D-FF101402
1mg | Discontinued | ||
2mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued |
Product Information
- 2-(3-(4-(4-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide
- 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide
- 2-{3-[4-(4-fluorophenyl)piperazin-1-yl]propyl}-2H-naphtho[1,8-cd][1,2]thiazole 1,1-dioxide
- 2H-Naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide
- Fananserin [USAN:INN]
- Rp 62203
- Unii-38Qj762Et6
Fananserin is a drug that acts as a selective antagonist of the 5-HT2 receptor. It has been shown to reduce food intake and body weight in experimental models. Fananserin has also been shown to have synergistic effects with fluoxetine, which may be due to its ability to block 5-HT2 receptors. The drug is not metabolized and is excreted unchanged in urine. In the brain, it mainly binds to the caudate putamen and occipital cortex. Fananserin has been shown to lower the glomerular filtration rate, which may be due to its interactions with gamma-aminobutyric acid (GABA) receptors. The drug also has activity as an agonist at 5-HT1A and 5-HT2C receptors, although this effect appears to be less potent than its interaction with GABA receptors.